In PDAC, neutralizing ARG1 metabolism targets the NETs of TANs, which helps restore the activity of CD8+ T cells in the tumor microenvironment, ultimately enhancing the effectiveness of immune checkpoint therapies [52]. This evidence concerns the gene CD8A and neoplasm.